Tommy B. Andersson

9.7k citations
120 papers · 7.2k · 1 hit paper · h-index 48

Impact in

  • Pharmacology top 0.02%
    • Pharmacogenetics and Drug Metabolism
    • Drug-Induced Hepatotoxicity and Protection
  • Hepatology top 0.5%
    • Liver physiology and pathology

Papers in

  • Pharmacology 77
    • Pharmacogenetics and Drug Metabolism 75
    • Drug-Induced Hepatotoxicity and Protection 18
  • Oncology 53
    • Drug Transport and Resistance Mechanisms 51
Co-authors
Kajsa P. Kanebratt (12 shared papers)Xueqing Li (8 shared papers)Magnus Ingelman‐Sundberg (17 shared papers)Collen Masimirembwa (15 shared papers)Lars Weidolf (5 shared papers)Inger Johansson (9 shared papers)Marianne Ridderström (6 shared papers)Charlotta Otter (6 shared papers)
Journals
Drug Metabolism and Disposition (28 papers)Journal of Pharmacology and Experimental Therapeutics (7 papers)Biochemical and Biophysical Research Communications (6 papers)Clinical Pharmacology & Therapeutics (5 papers)Biochemical Pharmacology (4 papers)
Partner nations
SwedenUnited KingdomUnited States

In The Last Decade

Tommy B. Andersson

118 papers receiving 7.0k citations

Tommy B. Andersson's Hit Papers

COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES 2004 · 496 citations
4960+7+14Years since publication100200300400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2004 Drug Metabolism and Disposition

Peers

Tommy B. Andersson
Comparison fields: 5 of 137
  • Pharmacology 2.9k
  • Hepatology 960
  • Oncology 1.7k
  • Gastroenterology 265
  • Transplantation 100
Replace Jiunn H. Lin with:
Jiunn H. Lin United States
Rommel G. Tirona Canada
Barbara J. Ring United States
Edward L. LeCluyse United States
Ross A. McKinnon Australia
Kent L. Kunze United States
Andrew Parkinson United States
Kathrin Klein Germany
Herbert L. Bonkovsky United States
Kazuto Yasuda United States
Tommy B. Andersson relative to Jiunn H. Lin United States Jiunn H. Lin's profile →
Citations per field
00.5×2×4×5.7×
Jiunn H. Lin · 1×
Citations per year

Countries citing papers authored by Tommy B. Andersson

Since Specialization
Citations

This map shows the geographic impact of Tommy B. Andersson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tommy B. Andersson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tommy B. Andersson more than expected).

Fields of papers citing papers by Tommy B. Andersson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tommy B. Andersson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tommy B. Andersson. The network helps show where Tommy B. Andersson may publish in the future.

Co-authors

The 25 scholars most cited alongside Tommy B. Andersson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tommy B. Andersson Line = papers co-authored together Tommy B. Andersson links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 120 papers — load more, or switch the sort, to bring in the rest.

#Work
1
COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES
Drug Metabolism and Disposition ·Xueqing Li, Tommy B. Andersson, Marie M. Ahlström, Lars Weidolf
Hit paper breakdown →		2004496
2
Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors
Clinical Pharmacokinetics ·Tommy B. Andersson
1996273
3
Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies
Drug Metabolism and Disposition ·Kajsa P. Kanebratt, Tommy B. Andersson
2008273
4
Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5′-Upstream Regulatory Region
Biochemical and Biophysical Research Communications ·Anna Westlind, Lena Löfberg, Niclas Tindberg, Tommy B. Andersson, Magnus Ingelman‐Sundberg
1999254
5
Stereoselective Metabolism of Omeprazole by Human Cytochrome P450 Enzymes
Drug Metabolism and Disposition ·Angela Äbelö, Tommy B. Andersson, Madeleine Antonsson, Anna Knuts Naudot, Inger Skånberg, Lars Weidolf
2000226
6
Amodiaquine Clearance and Its Metabolism to N-Desethylamodiaquine Is Mediated by CYP2C8: A New High Affinity and Turnover Enzyme-Specific Probe Substrate
Journal of Pharmacology and Experimental Therapeutics ·Xueqing Li, Anders Björkman, Tommy B. Andersson, Marianne Ridderström, Collen Masimirembwa
2002216
7
Functional coupling of human pancreatic islets and liver spheroids on-a-chip: Towards a novel human ex vivo type 2 diabetes model
Scientific Reports ·Sophie Bauer, Charlotte Wennberg Huldt, Kajsa P. Kanebratt, Isabell Durieux, Daniela Gunne, Shalini Andersson, Lorna Ewart, William G. Haynes, Ilka Maschmeyer, Annika Winter, Carina Ämmälä, Uwe Marx, Tommy B. Andersson
2017210
8
COMPARATIVE ANALYSIS OF CYP3A EXPRESSION IN HUMAN LIVER SUGGESTS ONLY A MINOR ROLE FOR CYP3A5 IN DRUG METABOLISM
Drug Metabolism and Disposition ·Anna Westlind-Johnsson, Sarah Malmebo, Anna L.V. Johansson, Charlotta Otter, Tommy B. Andersson, Inger Johansson, Robert J. Edwards, Alan R. Boobis, Magnus Ingelman‐Sundberg
2003202
9
The HepaRG cell line: a uniquein vitrotool for understanding drug metabolism and toxicology in human
Expert Opinion on Drug Metabolism & Toxicology ·Tommy B. Andersson, Kajsa P. Kanebratt, J. Gerry Kenna
2012192
10
Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates
Chemical Research in Toxicology ·Volker M. Lauschke, Delilah Hendriks, Catherine C. Bell, Tommy B. Andersson, Magnus Ingelman‐Sundberg
2016191
11
Identification of human cytochrome P 450 s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data
European Journal of Clinical Pharmacology ·Xueqing Li, Anders Bj�rkman, Tommy B. Andersson, Lars L. Gustafsson, Collen Masimirembwa
2003183
12
HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in Humans
Drug Metabolism and Disposition ·Kajsa P. Kanebratt, Tommy B. Andersson
2007161
13
Metabolic Stability for Drug Discovery and Development
Clinical Pharmacokinetics ·Collen Masimirembwa, Ulf Bredberg, Tommy B. Andersson
2003150
14
Cloning and Tissue Distribution of a Novel Human Cytochrome P450 of the CYP3A Subfamily, CYP3A43
Biochemical and Biophysical Research Communications ·Anna Westlind, Sarah Malmebo, Inger Johansson, Charlotta Otter, Tommy B. Andersson, Magnus Ingelman‐Sundberg, Mikael Oscarson
2001147
15
Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell–Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury
Drug Metabolism and Disposition ·Catherine C. Bell, Volker M. Lauschke, Sabine U. Vorrink, Henrik Palmgren, Rodger Duffin, Tommy B. Andersson, Magnus Ingelman‐Sundberg
2017143
16
In Vitro Evaluation of Potential Drug-Drug Interactions with Ticagrelor: Cytochrome P450 Reaction Phenotyping, Inhibition, Induction, and Differential Kinetics
Drug Metabolism and Disposition ·Diansong Zhou, Tommy B. Andersson, Scott Grimm
2010116
17
Drug-Induced Liver Injury in Humans: The Case of Ximelagatran
Handbook of experimental pharmacology ·Marianne Keisu, Tommy B. Andersson
2009112
18
4β‐Hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half‐life of elimination after induction with rifampicin
British Journal of Clinical Pharmacology ·Ulf Diczfalusy, Kajsa P. Kanebratt, Eva Bredberg, Tommy B. Andersson, Ylva Böttiger, Leif Bertilsson
2008110
19
Variability in Mass Spectrometry-based Quantification of Clinically Relevant Drug Transporters and Drug Metabolizing Enzymes
Molecular Pharmaceutics ·Christine Wegler, Fabienne Z. Gaugaz, Tommy B. Andersson, Jacek R. Wiśniewski, Diana Busch, Christian Gröer, Stefan Oswald, Agneta Norén, F. T. Weiss, Helen Hammer, Thomas Joos, Oliver Poetz, Brahim Achour, Amin Rostami‐Hodjegan, Evita van de Steeg, Heleen M. Wortelboer, Per Artursson
2017103
20
Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation
Hepatology ·Volker M. Lauschke, Sabine U. Vorrink, Sabrina Moro, Fatemah Rezayee, Åsa Nordling, Delilah Hendriks, Catherine C. Bell, Rowena Sison‐Young, B. Kevin Park, Christopher E. Goldring, Ewa Ellis, Inger Johansson, Souren Mkrtchian, Tommy B. Andersson, Magnus Ingelman‐Sundberg
201697

About Tommy B. Andersson

Tommy B. Andersson is a scholar working on Pharmacology, Oncology, Molecular Biology, Hepatology and Surgery, having authored 120 papers that have together received 7.2k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (75 papers), Drug Transport and Resistance Mechanisms (51 papers), Liver physiology and pathology (21 papers), Drug-Induced Hepatotoxicity and Protection (18 papers), Computational Drug Discovery Methods (12 papers), Pharmacological Effects and Toxicity Studies (10 papers), 3D Printing in Biomedical Research (10 papers) and Analytical Chemistry and Chromatography (9 papers). The work is most often cited by research in Pharmacology (2.9k citations), Hepatology (960 citations), Oncology (1.7k citations), Gastroenterology (265 citations) and Transplantation (100 citations). Tommy B. Andersson has collaborated with scholars based in Sweden, United Kingdom and United States. Frequent co-authors include Kajsa P. Kanebratt, Xueqing Li, Magnus Ingelman‐Sundberg, Collen Masimirembwa, Lars Weidolf, Inger Johansson, Marianne Ridderström, Charlotta Otter, Volker M. Lauschke and Catherine C. Bell. Their work appears in journals such as Drug Metabolism and Disposition, Journal of Pharmacology and Experimental Therapeutics, Biochemical and Biophysical Research Communications, Clinical Pharmacology & Therapeutics and Biochemical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiunn H. LinBreakdown of academic impact, for papers by Rommel G. TironaBreakdown of academic impact, for papers by Barbara J. RingBreakdown of academic impact, for papers by Edward L. LeCluyseBreakdown of academic impact, for papers by Ross A. McKinnonBreakdown of academic impact, for papers by Kent L. KunzeBreakdown of academic impact, for papers by Andrew ParkinsonBreakdown of academic impact, for papers by Kathrin KleinBreakdown of academic impact, for papers by Herbert L. BonkovskyBreakdown of academic impact, for papers by Kazuto Yasuda